Open access
Sep 2026
Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.
BACKGROUND Treatment options for paediatric patients with psoriasis are limited, and additional, more advanced therapies are needed. Risankizumab is an interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis in adults. OBJECTIVES To evaluate efficacy and safety of risankizumab through 52 weeks in paed...
N. Magnolo, Wine Lee Lara, A. Reich et al.
· British Journal of Dermatolo... · 0 citations